Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.[1]
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.[2][3][4]
Leen Kawas served as the company's first President and CEO,[5] but resigned in October 2021,[6] after an independent special committee found she "altered images in scientific papers she authored."[7] On October 21, 2021, Mark Litton, Ph.D., M.B.A. became Chief Executive Officer.[7]
The company has received financial support from venture capitalist groups and angel investors through four rounds of funding to date. [8] Athira Pharma was known as M3 Biotechnology until it underwent a name change on April 11, 2019.[9][10]
Core technologyEdit
The company's lead asset, ATH-1017, is in human trials of Alzheimer's disease as of 2021.[11] ATH-1017 is a small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in normal central nervous system function.[12] It aims to regenerate lost connections in the brain, protect brain cells from further damage, and prevent additional neuronal deterioration. [13] ATH-1017 is currently being tested in two clinical studies: ACT-AD and LIFT-AD.[14]
ReferencesEdit
^"Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update". Athira Pharma. 2021-08-16. Retrieved 2021-10-20.
^"First Trial of Alzheimer's Drug Underway | Science and Enterprise". sciencebusiness.technewslit.com. Retrieved 2018-10-15.
^"Individual Grants | Life Sciences Discovery Fund". www.lsdfa.org. Retrieved 2018-07-31.
^"Entrepreneurship has grown on M3 Biotechnology's CEO". The Seattle Times. 2017-04-30. Retrieved 2018-07-31.
^"Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer". Athira Pharma - Company Press Releases. October 21, 2021. Retrieved July 10, 2022.
^ abSoper, Taylor (October 21, 2021). . GeekWire. Archived from the original on October 21, 2021. Retrieved July 10, 2022.
^"M3 Biotechnology Launches Clinical Trials for Alzheimer's Disease Drug Focused on Restoring Lost Connections in the Brain". Retrieved 2018-10-15.
^Athira Pharma (2021-08-24). "A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease". {{cite journal}}: Cite journal requires |journal= (help)
External linksEdit
Official website
October 23, 2023
athira, pharma, major, contributor, this, article, appears, have, close, connection, with, subject, require, cleanup, comply, with, wikipedia, content, policies, particularly, neutral, point, view, please, discuss, further, talk, page, march, 2019, learn, when. A major contributor to this article appears to have a close connection with its subject It may require cleanup to comply with Wikipedia s content policies particularly neutral point of view Please discuss further on the talk page March 2019 Learn how and when to remove this template message Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer s disease and Parkinson s disease The company s lead candidate ATH 1017 is in human studies for Alzheimer s disease as of 2021 1 Athira Pharma Inc Traded asNasdaq ATHAIndustryBiotechnology PharmaceuticalsFounded2011HeadquartersSeattle United StatesProductsATH 1017Websitewww wbr athira wbr comThe company was founded in 2011 and is headquartered in Seattle Funding that supports the company is from both public and private investment groups including the Alzheimer s Drug Discovery Foundation Dolby Family Ventures the State of Washington s Life Sciences Discovery Fund The W Fund WRF Capital and other private investors 2 3 4 Leen Kawas served as the company s first President and CEO 5 but resigned in October 2021 6 after an independent special committee found she altered images in scientific papers she authored 7 On October 21 2021 Mark Litton Ph D M B A became Chief Executive Officer 7 Contents 1 History 2 Core technology 3 References 4 External linksHistory EditThe company has received financial support from venture capitalist groups and angel investors through four rounds of funding to date 8 Athira Pharma was known as M3 Biotechnology until it underwent a name change on April 11 2019 9 10 Core technology EditThe company s lead asset ATH 1017 is in human trials of Alzheimer s disease as of 2021 11 ATH 1017 is a small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor HGF and its receptor MET which are expressed in normal central nervous system function 12 It aims to regenerate lost connections in the brain protect brain cells from further damage and prevent additional neuronal deterioration 13 ATH 1017 is currently being tested in two clinical studies ACT AD and LIFT AD 14 References Edit Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update Athira Pharma 2021 08 16 Retrieved 2021 10 20 ADDF Funding Advances M3 Biotechnology Toward Clinical Trials Alzheimer s Drug Discovery Foundation www alzdiscovery org Retrieved 2018 10 15 First Trial of Alzheimer s Drug Underway Science and Enterprise sciencebusiness technewslit com Retrieved 2018 10 15 Individual Grants Life Sciences Discovery Fund www lsdfa org Retrieved 2018 07 31 Entrepreneurship has grown on M3 Biotechnology s CEO The Seattle Times 2017 04 30 Retrieved 2018 07 31 Athira Pharma Announces Leadership Changes Mark Litton Ph D M B A Named President and Chief Executive Officer Rachel Lenington M B A Named Chief Operating Officer Athira Pharma Company Press Releases October 21 2021 Retrieved July 10 2022 a b Soper Taylor October 21 2021 Ex Athira Pharma CEO Leen Kawas resigns and leaves board after image manipulation investigation GeekWire Archived from the original on October 21 2021 Retrieved July 10 2022 M3 Biotechnology Company Profile Valuation amp Investors PitchBook pitchbook com Retrieved 2018 10 15 Inc Athira Pharma M3 Biotechnology Announces Name Change to Athira Pharma Inc www prnewswire com Retrieved 2019 04 15 a href Template Cite web html title Template Cite web cite web a last has generic name help Alzheimer s focused M3 Biotechnology rebrands as Athira Pharma FierceBiotech Retrieved 2021 10 20 Delgado Diana Campelo Dosing Starts in Phase 2 3 Trial of Athira s ATH 1017 for Alzheimer s Retrieved 2021 08 30 Our Approach Athira Pharma Retrieved 2021 10 20 M3 Biotechnology Launches Clinical Trials for Alzheimer s Disease Drug Focused on Restoring Lost Connections in the Brain Retrieved 2018 10 15 Athira Pharma 2021 08 24 A Randomized Placebo Controlled Translational Study of ATH 1017 in Subjects With Mild to Moderate Alzheimer s Disease a href Template Cite journal html title Template Cite journal cite journal a Cite journal requires journal help External links EditOfficial website Retrieved from https en wikipedia org w index php title Athira Pharma amp oldid 1106783793, wikipedia, wiki, book, books, library,
